Jeffrey R. Stewart - 09 Nov 2026 Form 4 Insider Report for AbbVie Inc. (ABBV)

Reporting relationship: EVP, CHIEF COMMERCIAL OFFICER
Issuer ticker: ABBV
Reported as of: 09 Nov 2026
Net transaction value: -$11,925,738
SEC form: 4
Accepted by SEC: 12 Nov 2026, 17:00:24 UTC
Prior SEC filing: 03 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ T.O. Odutayo, Attorney-in-Fact for Jeffrey R. Stewart

Filing notes and source

Key filing fact

Jeffrey R. Stewart filed Form 4 for AbbVie Inc. (ABBV) on 12 Nov 2026.

Key facts

This page summarizes Jeffrey R. Stewart's Form 4 filing for AbbVie Inc. (ABBV).
6 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 12 Nov 2026, 17:00.

Change

Previous filing in this sequence was filed on 03 Mar 2026.
Current net transaction value: -$11,925,738.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001761675 Primary reporting owner

Stewart Jeffrey Ryan

Relationship: EVP, CHIEF COMMERCIAL OFFICER
Address: 1 N. WAUKEGAN ROAD, NORTH CHICAGO
Signature: /s/ T.O. Odutayo, Attorney-in-Fact for Jeffrey R. Stewart
Signature date: 12 Nov 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ABBV transaction

Common Stock, $0.01 par value

Options Exercise

Transaction value
Shares: +16,070
Change %: +19%
Price: $114.36^*
Shares after: 99,241
Date: 09 Nov 2026
Ownership: Direct

ABBV transaction

Common Stock, $0.01 par value

Options Exercise

Transaction value
Shares: +24,549
Change %: +25%
Price: $93.50^*
Shares after: 123,790
Date: 09 Nov 2026
Ownership: Direct

ABBV transaction

Common Stock, $0.01 par value

Sale

Transaction value: -$11,925,738
Shares: -40,619
Change %: -33%
Price: $293.60
Shares after: 83,171
Date: 09 Nov 2026
Ownership: Direct
Footnotes: F1

ABBV transaction

Common Stock, $0.01 par value

Gift

Transaction value
Shares: -3,450
Change %: -4.1%
Price: $0.000000^*
Shares after: 79,721
Date: 12 Nov 2026
Ownership: Direct

ABBV holding

Common Stock, $0.01 par value

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 1,338
Date: 09 Nov 2026
Ownership: By spouse in trust
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ABBV transaction Derivative

Option (Right to Buy)

Options Exercise

Transaction value
Shares: -16,070
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 09 Nov 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 16,070
Exercise price: $114.36
Footnotes: F3

ABBV transaction Derivative

Option (Right to Buy)

Options Exercise

Transaction value
Shares: -24,549
Change %: -50%
Price: $0.000000^*
Shares after: 24,550
Date: 09 Nov 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 24,549
Exercise price: $93.50
Footnotes: F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $293.54 to $293.82, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote

Footnote F2

The reporting person disclaims beneficial ownership of all securities held by his spouse.

Footnote F3

Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 5,357 on February 15, 2019, 5,356 on February 15, 2020, and 5,357 on February 15, 2021.

Footnote F4

Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 16,367 on February 20, 2021, 16,366 on February 20, 2022, and 16,366 on February 20, 2023.